Vaccination of Patients with Advanced Ovarian Carcinoma with the Anti-Idiotype ACA125: Immunological Response and Survival (Phase Ib/II)

Clinical Cancer Research

Volumn 10, Issue 5, 2004, Pages 1580-1587

  Reinartz, Silke ^a   Köhler, Siegmund ^a   Schlebusch, Harald ^b   Krista, Karl ^b   Giffels, Patrick ^a   Renke, Kirsten ^a   Huober, Jens ^c   Möbus, Volker ^d   Kreienberg, Rolf ^e   DuBois, Andreas ^f   Sabbatini, Paul ^g   Wagner, Uwe ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b CellControl Biomed Laboratories AG   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d Eye Hospital   (Germany)

^e UNIVERSITY OF ULM   (Germany)

^f DR HORST SCHMIDT KLINIKEN   (Germany)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DOXORUBICIN; IDIOTYPIC ANTIBODY; IDIOTYPIC ANTIBODY AC125; PACLITAXEL; TOPOTECAN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SURVIVAL; VOMITING;

ANIMALS; CA-125 ANTIGEN; CANCER VACCINES; FEMALE; HUMANS; ISOANTIBODIES; MICE; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 12144287745     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0056     Document Type: Article

References (29)

1. McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., and Davidson, M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med., 334: 1-6, 1996.
2. Kirby, T. O., Huh, W., and Alvarez, R. Immunotherapy of ovarian cancer. Exp. Opin. Biol. Ther., 2: 409-417, 2002.
3. Jerne, N. K. Towards a network theory of the immune system. Ann. Immunol. (Paris), 125: 373-389, 1974.
4. Cerny, J., and Hiemaux, J. Concept of idiotypic network: description and functions. In: J. Cerny and J. Hiemaux (eds.), Idiotypic Network and Diseases, pp. 12-30. Washington, DC: American Society for Microbiology, 1990.
5. Varela, F., and Coutinho, A. Second generation immune networks. Immunol. Today, 12: 159-166, 1991.
6. Jefferis, R. What is an idiotype? Immunol. Today, 14: 119-121, 1993.
7. Chatterjee, M., Foon, K., and Köhler, H. Idiotypic antibody immunotherapy of cancer. Cancer Immunol. Immunother., 38: 75-82, 1994.
8. Herlyn, D., Benden, A., Kane, M., Somasundaram, E., Zaloudik, J., Sperlagh, M., Hart, E., Ralph, C., Wettendorff, M., and Mastrangelo, M. Anti-idiotype cancer vaccines: pre-clinical and clinical studies. In Vivo, 5: 615-624, 1991.
9. Herlyn, D., Zaloudik, J., Somasundaram, R., Jakob, L., Benden, A., and Mastrangelo, M. Anti-idiotype vaccine in colo-rectal cancer patients. Hybridoma, 12: 515-520, 1993.
10. Foon, K., Chakraborty, M., John, W., Sheratt, A., and Köhler, H. Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype vaccine. J. Clin. Investig., 96: 334-342, 1995.
11. Foon, K., and Bhattacharya-Chatterjee, M. Idiotype vaccines in the clinic. Nat. Med., 4: 870-874, 1998.
12. Foon, K., John, W. J., Chakraborty, M., Das, R., Teitelbaum, A., Garrison, J., Kashala, O., Chatterjee, S. K., and Bhattacharya-Chatterjee, M. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J. Clin. Oncol., 17: 2889-2895, 1999.
13. Mittelman, A., Chen, Z., Yang, H., Wong, G., and Ferrone, S. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc. Natl. Acad. Sci. USA, 89: 466-470, 1992.
14. Pride, M. W., Shuey, S., Grillo-Lopez, A., Braslawsky, G., Ross, M., Legha, S. S., Eton, O., Buzaid, A., Ioannides, C., and Murray, J. L. Enhancement of cell-mediated immunità in melanoma patients immunized with murine anti-idiotypic monoclonal antibodies (MELIM-MUNE) that mimic the high molecular weight proteoglycan antigen. Clin. Cancer Res., 4: 2363-2370, 1998.
15. Foon, K. A., Lutzky, J., Baral, R. N., Yannelli, J. R., Hutchins, L., Teitelbaum, A., Kashala, O. L., Das, R., Garrison, J., Reisfeld, R. A., and Bhattacharya-Chatterjee, M. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J. Clin. Oncol., 18: 376-384, 2000.
16. Wagner, U., Köhler, S., Reinartz, S., Giffels, P., Huober, J., Renke, K., Schlebusch, H., Biersack, H. J., Möbus, V., Kreienberg, R., et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. Clin. Cancer Res., 7: 1154-1162, 2001.
17. Wagner, U. Antitumor antibodies for immunotherapy of ovarian carcinoma. Hybridoma, 12: 521-528, 1993.
18. Wagner, U., Schlebusch, H., Köhler, S., Schmolling, J., Grünn, U., and Krebs, D. Immunological responses to the tumor-associated antigen CA125 in patients with advanced ovarian cancer induced by murine monoclonal anti-idiotype vaccine ACA125. Hybridoma, 16: 33-40, 1997.
19. Wagner, U., Schlebusch, H., Schmolling, J., Reinsberg, J., and Krebs, D. Anti-idiotypes in ovarian cancer. In: Y. Shoenfeld, R. Kenedy, and S. Ferrone (eds.), Idiotypes in Medicine, Autoimmunity, Infection and Cancer, pp. 499-511. Amsterdam: Elsevier, 1998.
20. Köhler, S., Prietl, G., Schmolling, J., Grünn, U., Fischer, H. P., Schlebusch, H., and Wagner, U. Immuntherapie des ovarialkarzinoms mit dem monoklonalen antikörper ACA125-Ergebnisse der Phase Ib Studie. GebFra, 58: 180-186, 1998.
21. Schlebusch, H., Wagner, U., Grünn, U., and Schultes, B. A monoclonal anti-idiotypic antibody ACA125 mimicking the tumor-associated antigen CA125 for immunotherapy of ovarian cancer. Hybridoma, 14: 167-174, 1995.
22. Reinartz, S., Wagner, U., Giffels, P., Gruenn, U., Schlebusch, H., and Wallwiener, D. Immunological properties of a single-chain fragment of the anti-idiotypic antibody ACA125. Cancer Immunol. Immunother., 49: 186-192, 2000.
23. Reinartz, S., Bömer, H., Köhler, S., von Rücker, A., Schlebusch, H., and Wagner, U. Evaluation of immunological responses in patients with ovarian cancer treated with the anti-idiotype vaccine ACA125 by determination of intracellular cytokines: a preliminary report. Hybridoma, 18: 41-45, 1999.
24. Grant, S. C., Kris, M. G., Houghton, A. N., and Chapman, P. B. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin. Clin. Cancer Res., 5: 1319-1323, 1999.
25. Eisenhauer, E. A., ten Bokkel Huinink, W. W., Swenerton, K. D., Gianni, L., Myles, J., van der Burg, M. E., Kerr, I., Vermorken, J. B., Buser, K., Colombo, N., et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J. Clin. Oncol., 12: 2654-2666, 1994.
26. Huinink, W. B., Gore, M., Carmicheal, J., Gordon, A., Malfetano, J., Hudson, I., Broom, C., Scarabelli, C., Davidson, N., Spanczynski, M., et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol., 15: 2183-2193, 1997.
27. Gordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E., and Lacave, A. J. Recurrent epithelial ovarian carcinoma: a randomized Phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol., 19: 3312-3322, 2001.
28. Rosenberg, P., Andersson, H., Boman, K., Ridderheim, M., Sorbe, B., Puistola, U., and Paro, G. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol., 41: 418-424, 2002.
29. Gore, M., Oza, A., Rustin, G., Malfetano, J., Calvert, H., Clarke-Pearson, D., Carmichael, J., Ross, G., Beckman, R. A., and Fields, S. Z. A randomized trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur. J. Cancer, 38: 57-63, 2002.